Friday, July 10, 2026

pharma · Prurigo Nodularis · Vitiligo

Incyte

Incyte clinical programs — 14 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

1801 Augustine Cut-Off, Wilmington, Delaware 19803, US HQ
3,381 Employees
NMPA registrant Type
Company details
Status
Public
HQ
1801 Augustine Cut-Off, Wilmington, Delaware 19803, US
Employees
3,381
Programs
53
Drugs
61
Patents
0
Intelligence · Clinical Programs

Incyte projects

14 ClinicalTrials.gov programs sponsored by Incyte.

Incyte has 14 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Axatilimab (INCA034176)

    Incyte

    Chronic Graft-Versus-Host Disease

    phase 2 small molecule active

    1 trial
  2. INCA34176-254

    Incyte

    chronic graft-versus-host disease

    phase 2 small molecule active

    1 trial
  3. INCAGN 2385-203

    Incyte

    In participants with PD-L1–positive and systemic therapy–naive R/M SCCHN.

    phase 2 small molecule active

    1 trial
  4. INCB 00928-104

    Incyte

    Anaemia associated with myelofibrosis

    phase 2 other active

    1 trial
  5. INCB 54707-208

    Incyte

    Treatment of patients with inadequately controlled moderate to severe asthma

    phase 2 small molecule active

    1 trial
  6. INCB 84344-102

    Incyte

    Recurrent or Refractory Leukemias, Lymphomas, and Solid Tumors

    phase 2 small molecule active

    1 trial
  7. INCB000928, Placebo

    Incyte

    Fibrodysplasia Ossificans Progressiva

    phase 2 small molecule active

    1 trial
  8. INCB099280, Adagrasib

    Incyte

    Advanced Solid Tumors Harboring a KRASG12C Mutation

    phase 2 small molecule active

    1 trial
  9. INCB123667-203

    Incyte

    Ovarian Cancer

    phase 2 other active

    1 trial
  10. INCMGA0012-204

    Incyte

    Endometrial cancer, Endometrial cancer

    phase 2 small molecule active

    1 trial
  11. Jakavi 5 mg tablets, Jakavi 15 mg tablets

    Incyte

    Myelofibrosis

    phase 2 small molecule active

    1 trial
  12. MOR208C115

    Incyte

    Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 2 small molecule active

    1 trial
  13. Parsaclisib

    Incyte

    Lymphoma

    phase 2 small molecule completed

    1 trial
  14. Pembrolizumab

    Incyte

    Lung Cancer

    phase 2 small molecule completed

    2 trials

Frequently asked questions

How many clinical projects does Incyte have?

14 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.